Researchers conducted a multicenter, randomized study to assess the continuation of renin-angiotensin system inhibition (RASI) before major non-cardiac surgery.
More than 50% of patients undergoing major surgery are on chronic RASI treatment. The primary objective of the study was to assess a composite of all-cause mortality and postoperative complications within 28 days after surgery.
The study included 2222 patients who were randomized into two groups: one that discontinued RASI treatment 3 days before surgery and another that continued medication until the day of surgery.
The primary endpoint occurred in 22% of patients in both groups. These results suggest that continuation of RASI treatment was not associated with a higher rate of perioperative complications, indicating that both strategies are acceptable.
Presented by Matthieu Legrand at the Hot-Line Sessions, ESC Congress 2024, August 30-September 2, London, England.
Subscribe to our weekly newsletter
Get the latest scientific articles on interventional cardiology
